Bacterial Infection
Conditions
Keywords
bacterial infection
Brief summary
* To determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection. * To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre and post intervention in the selected medical centers.
Interventions
DRUGExtended-Spectrum-Lactamases (ESBLs)
Sponsors
Wyeth is now a wholly owned subsidiary of Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients admitted or transferred to the ICU/pulmonary/hematology units. * Patients of either sex, 18 years of age or older
Exclusion criteria
* Pregnant and nursing women. Female of childbearing potential without using any birth control methods. Female of childbearing potential using oral contraceptives during study period. (Note: penicillin and beta-lactamase inhibitors may prevent oral contraceptives from working properly, increasing the chance of pregnancy). * Patients who have the contraindications of using Tazocin (pipercillin/tazobactam) Other exclusions apply.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| Infection rate of ESBL producing E. coli or K. Pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months) | — |
Outcome results
None listed